Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma

Pathology Research and Practice

Volumn 208, Issue 8, 2012, Pages 462-469

  Ha, Sang Yun ^a   Kim, Seok Hyung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bmi1; Esophageal squamous cell carcinoma; EZH2; Polycomb repressive protein; PRC

Indexed keywords

BMI1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; UPREGULATION;

AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; REPUBLIC OF KOREA; TUMOR MARKERS, BIOLOGICAL;

EID: 84864112566     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.05.012     Document Type: Article

References (50)

1. Arisan S., Buyuktuncer E.D., Palavan-Unsal N., Caskurlu T., Cakir O.O., Ergenekon E. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol. Int. 2005, 75:252-257.
2. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., Salvesen H.B., Otte A.P., Akslen L.A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 2006, 24:268-273.
3. Bachmann I.M., Puntervoll H.E., Otte A.P., Akslen L.A. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod. Pathol. 2008, 21:583-590.
4. Berezovska O.P., Glinskii A.B., Yang Z., Li X.M., Hoffman R.M., Glinsky G.V. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006, 5:1886-1901.
5. Bommi P.V., Dimri M., Sahasrabuddhe A.A., Khandekar J., Dimri G.P. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 2010, 9:2663-2673.
6. Breuer R.H., Snijders P.J., Smit E.F., Sutedja T.G., Sewalt R.G., Otte A.P., van Kemenade F.J., Postmus P.E., Meijer C.J., Raaphorst F.M. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 2004, 6:736-743.
7. Cai G.H., Wang K., Miao Q., Peng Y.S., Chen X.Y. Expression of polycomb protein EZH2 in multi-stage tissues of gastric carcinogenesis. J. Dig. Dis. 2010, 11:88-93.
8. Cao Q., Yu J., Dhanasekaran S.M., Kim J.H., Mani R.S., Tomlins S.A., Mehra R., Laxman B., Cao X., Kleer C.G., Varambally S., Chinnaiyan A.M. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284.
9. Cao W., Feng Z., Cui Z., Zhang C., Sun Z., Mao L., Chen W. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer 2011.
10. Chase A., Cross N.C. Aberrations of EZH2 in cancer. Clin. Cancer Res. 2011, 17:2613-2618.
11. Chen H., Tu S.W., Hsieh J.T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J. Biol. Chem. 2005, 280:22437-22444.
12. Choi Y.J., Choi Y.L., Cho E.Y., Shin Y.K., Sung K.W., Hwang Y.K., Lee S.J., Kong G., Lee J.E., Kim J.S., Kim J.H., Yang J.H., Nam S.J. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res. Treat. 2009, 113:83-93.
13. Collett K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A., Aas T., Otte A.P., Akslen L.A. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 2006, 12:1168-1174.
14. Engelsen I.B., Mannelqvist M., Stefansson I.M., Carter S.L., Beroukhim R., Oyan A.M., Otte A.P., Kalland K.H., Akslen L.A., Salvesen H.B. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br. J. Cancer 2008, 98:1662-1669.
15. Fujii S., Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci. 2008, 99:738-746.
16. Huqun, Ishikawa R., Zhang J., Miyazawa H., Goto Y., Shimizu Y., Hagiwara K., Koyama N. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 2011.
17. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
18. Kang M.K., Kim R.H., Kim S.J., Yip F.K., Shin K.H., Dimri G.P., Christensen R., Han T., Park N.H. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br. J. Cancer 2007, 96:126-133.
19. Kidani K., Osaki M., Tamura T., Yamaga K., Shomori K., Ryoke K., Ito H. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol. 2009, 45:39-46.
20. Kikuchi J., Kinoshita I., Shimizu Y., Kikuchi E., Konishi J., Oizumi S., Kaga K., Matsuno Y., Nishimura M., Dosaka-Akita H. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010, 116:3015-3024.
21. Kim J.H., Yoon S.Y., Jeong S.H., Kim S.Y., Moon S.K., Joo J.H., Lee Y., Choe I.S., Kim J.W. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 2004, 13:383-388.
22. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., Chinnaiyan A.M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11606-11611.
23. Kodach L.L., Jacobs R.J., Heijmans J., van Noesel C.J., Langers A.M., Verspaget H.W., Hommes D.W., Offerhaus G.J., van den Brink G.R., Hardwick J.C. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 2010, 31:1567-1575.
24. Laitinen S., Martikainen P.M., Tolonen T., Isola J., Tammela T.L., Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int. J. Cancer 2008, 122:595-602.
25. Levine S.S., King I.F., Kingston R.E. Division of labor in polycomb group repression. Trends Biochem. Sci. 2004, 29:478-485.
26. Lin Y.W., Chen H.M., Fang J.Y. Gene silencing by the Polycomb group proteins and associations with cancer. Cancer Invest. 2011, 29:187-195.
27. Liu J.H., Song L.B., Zhang X., Guo B.H., Feng Y., Li X.X., Liao W.T., Zeng M.S., Huang K.H. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J. Surg. Oncol. 2008, 97:267-272.
28. Liu W.L., Guo X.Z., Zhang L.J., Wang J.Y., Zhang G., Guan S., Chen Y.M., Kong Q.L., Xu L.H., Li M.Z., Song L.B., Zeng M.S. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer 2010, 10:467.
29. Lund A.H., van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr. Opin. Cell Biol. 2004, 16:239-246.
30. Matsukawa Y., Semba S., Kato H., Ito A., Yanagihara K., Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006, 97:484-491.
31. Mimori K., Ogawa K., Okamoto M., Sudo T., Inoue H., Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur. J. Surg. Oncol. 2005, 31:376-380.
32. Pietersen A.M., Horlings H.M., Hauptmann M., Langerod A., Ajouaou A., Cornelissen-Steijger P., Wessels L.F., Jonkers J., van de Vijver M.J., van Lohuizen M. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 2008, 10:R109.
33. Qin Z.K., Yang J.A., Ye Y.L., Zhang X., Xu L.H., Zhou F.J., Han H., Liu Z.W., Song L.B., Zeng M.S. Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer 2009, 9:61.
34. Raaphorst F.M., van Kemenade F.J., Blokzijl T., Fieret E., Hamer K.M., Satijn D.P., Otte A.P., Meijer C.J. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am. J. Pathol. 2000, 157:709-715.
35. Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., Gudas L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 2005, 11:8570-8576.
36. Sasaki M., Ikeda H., Itatsu K., Yamaguchi J., Sawada S., Minato H., Ohta T., Nakanuma Y. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab. Invest. 2008, 88:873-882.
37. Silva J., Garcia V., Garcia J.M., Pena C., Dominguez G., Diaz R., Lorenzo Y., Hurtado A., Sanchez A., Bonilla F. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res. 2007, 9:R55.
38. Sinicrope F.A., Ruan S.B., Cleary K.R., Stephens L.C., Lee J.J., Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995, 55:237-241.
39. Song L.B., Zeng M.S., Liao W.T., Zhang L., Mo H.Y., Liu W.L., Shao J.Y., Wu Q.L., Li M.Z., Xia Y.F., Fu L.W., Huang W.L., Dimri G.P., Band V., Zeng Y.X. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66:6225-6232.
40. Sung C.O., Han S.Y., Kim S.H. Low expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2011, 18:273-281.
41. Tan J., Yang X., Zhuang L., Jiang X., Chen W., Lee P.L., Karuturi R.K., Tan P.B., Liu E.T., Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21:1050-1063.
42. van Kemenade F.J., Raaphorst F.M., Blokzijl T., Fieret E., Hamer K.M., Satijn D.P., Otte A.P., Meijer C.J. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001, 97:3896-3901.
43. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
44. Vonlanthen S., Heighway J., Altermatt H.J., Gugger M., Kappeler A., Borner M.M., van Lohuizen M., Betticher D.C. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br. J. Cancer 2001, 84:1372-1376.
45. Vrzalikova K., Skarda J., Ehrmann J., Murray P.G., Fridman E., Kopolovic J., Knizetova P., Hajduch M., Klein J., Kolek V., Radova L., Kolar Z. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J. Cancer Res. Clin. Oncol. 2008, 134:1037-1042.
46. Wang H., Albadine R., Magheli A., Guzzo T.J., Ball M.W., Hinz S., Schoenberg M.P., Netto G.J., Gonzalgo M.L. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol. Oncol. 2011.
47. Wang H., Pan K., Zhang H.K., Weng D.S., Zhou J., Li J.J., Huang W., Song H.F., Chen M.S., Xia J.C. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134:535-541.
48. Weikert S., Christoph F., Kollermann J., Muller M., Schrader M., Miller K., Krause H. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med. 2005, 16:349-353.
49. Yamada A., Fujii S., Daiko H., Nishimura M., Chiba T., Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int. J. Oncol. 2011, 38:345-353.
50. Yonemitsu Y., Imazeki F., Chiba T., Fukai K., Nagai Y., Miyagi S., Arai M., Aoki R., Miyazaki M., Nakatani Y., Iwama A., Yokosuka O. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum. Pathol. 2009, 40:1304-1311.